Assertio Holdings, Inc. (ASRT)
NASDAQ: ASRT · Real-Time Price · USD
0.7200
+0.0082 (1.15%)
At close: Dec 19, 2025, 4:00 PM EST
0.7101
-0.0099 (-1.38%)
After-hours: Dec 19, 2025, 6:03 PM EST
Assertio Holdings Revenue
Assertio Holdings had revenue of $49.46M in the quarter ending September 30, 2025, with 69.36% growth. This brings the company's revenue in the last twelve months to $137.35M, up 9.21% year-over-year. In the year 2024, Assertio Holdings had annual revenue of $124.96M, down -17.83%.
Revenue (ttm)
$137.35M
Revenue Growth
+9.21%
P/S Ratio
0.50
Revenue / Employee
$2,368,172
Employees
58
Market Cap
69.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 124.96M | -27.11M | -17.83% |
| Dec 31, 2023 | 152.07M | -4.17M | -2.67% |
| Dec 31, 2022 | 156.23M | 45.22M | 40.73% |
| Dec 31, 2021 | 111.01M | 4.74M | 4.46% |
| Dec 31, 2020 | 106.28M | -123.23M | -53.69% |
| Dec 31, 2019 | 229.50M | -82.27M | -26.39% |
| Dec 31, 2018 | 311.77M | -68.95M | -18.11% |
| Dec 31, 2017 | 380.72M | -75.17M | -16.49% |
| Dec 31, 2016 | 455.90M | 113.16M | 33.02% |
| Dec 31, 2015 | 342.74M | -47.63M | -12.20% |
| Dec 31, 2014 | 390.36M | 256.16M | 190.87% |
| Dec 31, 2013 | 134.21M | 43.39M | 47.78% |
| Dec 31, 2012 | 90.82M | -42.16M | -31.70% |
| Dec 31, 2011 | 132.97M | 52.21M | 64.64% |
| Dec 31, 2010 | 80.76M | 23.04M | 39.90% |
| Dec 31, 2009 | 57.73M | 22.89M | 65.69% |
| Dec 31, 2008 | 34.84M | -30.74M | -46.87% |
| Dec 31, 2007 | 65.58M | 56.03M | 586.65% |
| Dec 31, 2006 | 9.55M | 5.15M | 116.82% |
| Dec 31, 2005 | 4.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ASRT News
- 5 weeks ago - Assertio Holdings, Inc. (ASRT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Assertio Reports Third Quarter 2025 Financial Results - Business Wire
- 7 weeks ago - Assertio Announces Leadership Transition - GlobeNewsWire
- 3 months ago - DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025 - GlobeNewsWire
- 3 months ago - Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV - GlobeNewsWire
- 3 months ago - Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association - GlobeNewsWire
- 3 months ago - Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 - GlobeNewsWire
- 4 months ago - Assertio Holdings, Inc. (ASRT) Q2 2025 Earnings Call Transcript - Seeking Alpha